Dr. Jerald P. Radich - CML - Chronic Myeloid Leukemia
'Jerald P. Radich, MD is a professor of medicine at University of Washington School of Medicine.
In addition, he acts as the medical director of the research trials office at Fred Hutchinson Cancer Research Center, and the director of the Lymphoid and Chronic Myeloid Leukemia Repository at Southwest Oncology Group in Seattle, Washington. Dr Radich studied epidemiology, earning a master’s of science degree, at Harvard University School of Public Health before attending University of California, Davis, School of Medicine. He did both his internship and residency in internal medicine at University of Washington Affiliated Hospitals before accepting a position as chief medical resident at the Veterans Administration Medical Center Affiliated Hospitals, also in Seattle. Dr Radich then took a fellowship in medical oncology at Fred Hutchinson Cancer Research Center, where he has subsequently remained. Dr Radich’s main research interest concerns the genetics of leukemia and the use of modern molecular biology techniques toward the early detection of cancer''
Extract of http://web.educationalconcepts.net/edconwebsite/MoreInfo.aspx?PUID=13110
VIDEOS
Getting Chronic Myelogenous Leukemia Into a Deeper Treatment Response
December 20, 2019, Patient Power
Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML
October 8, 2016, OncLive
CML Takeaways From ASH 2015: Discontinuing Tyrosine Kinase Inhibitors
December 22, 2015, Medscape Oncology
Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?
2015, Harborside Press
Who should still be transplanted for CML in 2015?
May 15, 2015, ImedexCME
Getting Chronic Myelogenous Leukemia Into a Deeper Treatment Response
December 20, 2019, Patient Power
Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML
October 8, 2016, OncLive
CML Takeaways From ASH 2015: Discontinuing Tyrosine Kinase Inhibitors
December 22, 2015, Medscape Oncology
Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?
2015, Harborside Press
Who should still be transplanted for CML in 2015?
May 15, 2015, ImedexCME
ARTICLES
Leukemia researcher Dr. Jerry Radich receives Kurt Enslein Endowed Chair
August 15, 2019, Fred Hutch
Taking the shortcut to frontline treatment
September 17, 2018, Fred Hutch
Incorporating Generic Imatinib Into Frontline Treatment for CML
October 1, 2016, OncLive
Chronic Myelogenous Leukemia: What Drug for Which Patient?
November 25, 2015, ASCOPOST
Emerging evidence is resolving questions in CML
October 23, 2015, Hematology News
Monitoring Response to Tyrosine Kinase Inhibitor Therapy, Mutational Analysis, and New Treatment Options in Chronic Myelogenous Leukemia
2013, JNCCN Journal of National Comprehensive Cancer Network
Leukemia researcher Dr. Jerry Radich receives Kurt Enslein Endowed Chair
August 15, 2019, Fred Hutch
Taking the shortcut to frontline treatment
September 17, 2018, Fred Hutch
Incorporating Generic Imatinib Into Frontline Treatment for CML
October 1, 2016, OncLive
Chronic Myelogenous Leukemia: What Drug for Which Patient?
November 25, 2015, ASCOPOST
Emerging evidence is resolving questions in CML
October 23, 2015, Hematology News
Monitoring Response to Tyrosine Kinase Inhibitor Therapy, Mutational Analysis, and New Treatment Options in Chronic Myelogenous Leukemia
2013, JNCCN Journal of National Comprehensive Cancer Network